World's Best Scientists 2026 revealed!
Oksana Suchowersky

Oksana Suchowersky

D-Index & Metrics

Neuroscience

D-Index
59
Citations
12542
World Ranking
4005
National Ranking
232

Best Publications

  • Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial

    R. Holloway;I. Shoulson;K. Kieburtz;M. McDermott

  • Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology

    J. M. Miyasaki;W. Martin;O. Suchowersky;W. J. Weiner

  • CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

    J.-M. Lee;E.M. Ramos;J.-H. Lee;T. Gillis

  • Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology

    O. Suchowersky;S. Reich;J. Perlmutter;T. Zesiewicz

  • The Canadian multicentre study of deep brain stimulation for cervical dystonia.

    Zelma H. T. Kiss;Kristina Doig-Beyaert;Michael Eliasziw;Joseph Tsui

  • Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology

    O. Suchowersky;G. Gronseth;J. Perlmutter;S. Reich

  • SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis.

    Guy A. Rouleau;Arthur W. Clark;Karen Rooke;Albena Pramatarova

  • Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk.

    Marlene Huggins;Maurice Bloch;Sandi Wiggins;Shelin Adam

  • Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period

    G-Y.R. Hsiung;S.K. Das;R. Ranawaya;A.-L. Lafontaine

  • Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease

    I H Richard;R Kurlan;C Tanner;S Factor

  • Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.

    Hubert H. Fernandez;David G. Standaert;Robert A. Hauser;Anthony E. Lang

  • Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease

    Cory Toth;Kim Breithaupt;Shaohua Ge;Yanjun Duan

  • Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease

    L. Djoussé;B. Knowlton;M. Hayden;E. W. Almqvist

  • A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS Study

    Jian Liang Li;Michael R. Hayden;Elisabeth W. Almqvist;Ryan R. Brinkman

  • Mutations in BICD2, which Encodes a Golgin and Important Motor Adaptor, Cause Congenital Autosomal-Dominant Spinal Muscular Atrophy

    Kornelia Neveling;Lilian A. Martinez-Carrera;Irmgard Hölker;Angelien Heister

  • Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.

    Mei Sun;Jeanne C. Latourelle;G. Frederick Wooten;Mark F. Lew

  • Relationship between trinucliotide repeats and neuropathological changes in Huntington's diease

    Sarah Furtado;Oksana Suchowersky;N. Barry Rewcastle;Lisa Graham

  • Impairment of pronation, supination, and body co-ordination in reach-to-grasp tasks in human Parkinson's disease (PD) reveals homology to deficits in animal models.

    Ian Q Whishaw;Oksana Suchowersky;Oksana Suchowersky;Leigh Davis;Justyna Sarna

  • Nursing time to program and assess deep brain stimulators in movement disorder patients.

    Karen Hunka;Oksana Suchowersky;Susan Wood;Lorelei Derwent

  • Canadian Guidelines on Parkinson's Disease.

    David Grimes;Joyce Gordon;Barbara Snelgrove;Ivy Lim-Carter

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Recently Published Articles